Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015 Jan 20, 2015
Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program Dec 9, 2014
Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium's Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older Dec 8, 2014
Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients Dec 1, 2014
Actinium Clinical Advisory Board Chair to Participate in the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Nov 11, 2014
Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension of Overall Survival to 9.1 Months in Elderly Secondary Acute Myeloid Leukemia Nov 6, 2014
Actinium Announces Collaboration With Albert Einstein College of Medicine on New Actinium Program Oct 27, 2014
